SYDNEY, Sept. 29, 2014 (GLOBE NEWSWIRE) -- Novogen Ltd. (ASX: NRT, NASDAQ: NVGN)
Graham Kelly PhD, CEO & Chairman attended the Rodman & Renshaw 16th Annual Global Investment Conference where he was interviewed by Ed Kershen, Equities.com providing an overview and history of Novogen Ltd. and CanTx Inc., including growth prospects brought about by new and unique technologies of Novogen Ltd and CanTx Inc. Novogen and CanTx new technologies as Dr Kelly explains have the potential to become the "go to" drugs for first line therapy in particular cancers.
Please follow the link;
http://www.equities.com/media-gallery/329-dr-graham-kelly-chairman-and-ceo-novogen- ltd?category_id=73
About Novogen Limited
Novogen is a public, Australian drug-development company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN'). The Novogen Group includes a New Haven CT - based joint venture company, CanTx Inc, with Yale University.
Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti- tropomyosins (ATMs). SBP compounds have been created to kill the full range of cells within a tumor, but particularly the cancer stem cells. The ATM compounds target the microfilament component of the cancer cell and when used in conjunction with standard anti- microtubular drugs, result in comprehensive and fatal destruction of the cancer cell's cytoskeleton. Ovarian cancer, colorectal cancer, malignant ascites, prostate cancer, neural cancers (glioblastoma, neuroblastoma) and melanoma are the key clinical indications being pursued, with the ultimate objective of employing both technologies as a unified approach to first-line therapy.
About CanTx
CanTx Inc is a private biotechnology company based in New Haven, Connecticut, and established as a joint venture between Novogen and Yale University. CanTx is dedicated to the development of anti-cancer drugs for the treatment of ovarian cancer.
Further information is available on the Company's website, www.novogen.com And www.can-tx.com